Pharmalot

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more

Pharmalot Ed Silverman

STAT Plus: Student group that ranked med schools over industry conflicts votes to accept pharma funding

Pharmalot Ed Silverman

STAT Plus: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits

Pharmalot Ed Silverman

STAT Plus: U.S. drug shortages have reached a decade high and are lasting longer, too

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an FDA meeting on MDMA, a new obesity pill, and more

Pharmalot Ed Silverman

STAT Plus: Leading CRO to pay record fine for badly neglecting hundreds of beagles in breeding facility

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zantac lawsuits, worries over MDMA for PTSD, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more

Pharmalot Ed Silverman

STAT Plus: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program

Pharmalot Ed Silverman

STAT Plus: Many docs who tweeted product endorsements also took money from manufacturers, analysis shows

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a deal for a Moderna bird flu shot, NIH trial shortcomings, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Merck deal, weight loss drugs, and lots more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more

Pharmalot Matthew Herper

STAT Plus: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more

Pharmalot Jonathan Wosen

STAT Plus: Pharmalittle: We’re watching a ban of compounded versions of GLP-1s, a Biogen acquisition, and more

Pharmalot Allison DeAngelis

STAT Plus: Pharmalittle: We’re watching BIO layoffs, AstraZeneca plans to double revenue, and more

Pharmalot Andrew Joseph

STAT Plus: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an Amgen drug for lung cancer, a Novo plant fire, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Roche obesity drug, an experimental Lilly insulin, and more

Pharmalot Ed Silverman

STAT Plus: Getting abortion pills through the mail is safe, quick, and effective, study finds

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about fake studies, AbbVie investing in psychiatric meds, and more

Pharmalot Ed Silverman

STAT Plus: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Pfizer’s DTC platform, Sandoz’s feud with a U.K. trade group, and more

Pharmalot Ed Silverman

STAT Plus: Sandoz disavows U.K. trade group over dispute about promoting a biosimilar for multiple sclerosis

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more

Pharmalot Ed Silverman

STAT Plus: FDA is criticized for taking a ‘ministerial’ role in sorting out some pharma patents